La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis

Company Overview

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $3.12 to $6.22
• 52-Week Range: N/A
• Volume: 66,708 shs
• Average Volume: 158,476 shs
• Market Capitalization: $155.11 million
• P/E Ratio: 51.84
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LJPC Stock Analysis - Frequently Asked Questions

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) announced its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The biopharmaceutical company earned $10.43 million during the quarter, compared to analyst estimates of $13.10 million. La Jolla Pharmaceutical had a negative trailing twelve-month return on equity of 5.46% and a net margin of 8.54%.

What other stocks do shareholders of La Jolla Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), El Pollo Loco (LOCO), Intercept Pharmaceuticals (ICPT), Bristol Myers Squibb (BMY), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 5/16/2022
• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LJPC
• CIK: 920465
• Web: www.lajollapharmaceutical.com
• Phone: (617) 715-3600
• Fax: 858-626-2851
• Employees: 61
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.12
• Trailing P/E Ratio: 51.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $19.66 million
• Net Margins: 8.54%
• Pretax Margin: 8.64%
• Return on Equity: -5.46%
• Return on Assets: 4.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.02
• Quick Ratio: 3.52

Sales & Book Value

• Annual Sales: $75.72 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 7.95
• Book Value: ($2.94) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 24,937,000
• Free Float: 15,885,000
• Market Cap: $155.11 million
• Optionable: Optionable
• Beta: 2.39